Dow Jones

40,003.59

0.34%

Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

Regístrate

REPH

Recro Pharma (REPH)

Recro Pharma Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:REPH

1 2 3 4 5 6 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
06/06/2023	15:38	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:REPH	Recro Pharma Inc
02/06/2023	15:32	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:REPH	Recro Pharma Inc
26/05/2023	15:08	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:REPH	Recro Pharma Inc
22/05/2023	16:11	Edgar (US Regulatory)	Report of Proposed Sale of Securities (144)	NASDAQ:REPH	Recro Pharma Inc
06/04/2023	07:26	Edgar (US Regulatory)	Proxy Statement (definitive) (def 14a)	NASDAQ:REPH	Recro Pharma Inc
24/03/2023	15:07	Edgar (US Regulatory)	Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)	NASDAQ:REPH	Recro Pharma Inc
01/03/2023	16:01	Edgar (US Regulatory)	Securities Registration: Employee Benefit Plan (s-8)	NASDAQ:REPH	Recro Pharma Inc
01/03/2023	15:52	Edgar (US Regulatory)	Annual Report (10-k)	NASDAQ:REPH	Recro Pharma Inc
16/12/2022	16:01	Edgar (US Regulatory)	Amended Statement of Beneficial Ownership (sc 13d/a)	NASDAQ:REPH	Recro Pharma Inc
13/12/2022	16:29	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)	NASDAQ:REPH	Recro Pharma Inc
09/11/2022	15:30	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:REPH	Recro Pharma Inc
06/09/2022	18:13	Edgar (US Regulatory)	Initial Statement of Beneficial Ownership (3)	NASDAQ:REPH	Recro Pharma Inc
05/07/2022	15:37	Edgar (US Regulatory)	Amended Tender Offer Statement by Issuer (sc To-i/a)	NASDAQ:REPH	Recro Pharma Inc
27/06/2022	16:22	Edgar (US Regulatory)	Statement of Beneficial Ownership (sc 13d)	NASDAQ:REPH	Recro Pharma Inc
01/06/2022	16:06	Edgar (US Regulatory)	Tender Offer Statement by Issuer (sc To-i)	NASDAQ:REPH	Recro Pharma Inc
20/04/2022	16:45	Edgar (US Regulatory)	Amended Statement of Changes in Beneficial Ownership (4/a)	NASDAQ:REPH	Recro Pharma Inc
04/04/2022	05:01	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:REPH	Recro Pharma Inc
21/03/2022	06:00	GlobeNewswire Inc.	Recro Announces Name Change to Societal CDMO to Reflect Corporate Expansion and Transformation	NASDAQ:REPH	Recro Pharma Inc
01/03/2022	15:05	GlobeNewswire Inc.	Recro Reports Fourth Quarter and Year End 2021 Financial Results	NASDAQ:REPH	Recro Pharma Inc
23/02/2022	06:00	GlobeNewswire Inc.	Recro Reports Progress Towards Launching Fill/Finish and Lyophilization Capabilities at San Diego Facility	NASDAQ:REPH	Recro Pharma Inc
22/02/2022	15:05	GlobeNewswire Inc.	Recro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022	NASDAQ:REPH	Recro Pharma Inc
14/02/2022	15:36	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)	NASDAQ:REPH	Recro Pharma Inc
11/02/2022	05:08	Edgar (US Regulatory)	Notice of Effectiveness (effect)	NASDAQ:REPH	Recro Pharma Inc
26/01/2022	06:00	GlobeNewswire Inc.	Recro Wins $1.5 Million Formulation Development and CGMP Manufacturing Contract to Support Clinical Development of Topical Treatment for Skin Cancer Prevention	NASDAQ:REPH	Recro Pharma Inc
19/01/2022	06:00	GlobeNewswire Inc.	Recro Appoints Eduardo Uribe as Head of Quality for Recro San Diego	NASDAQ:REPH	Recro Pharma Inc
18/01/2022	06:20	Edgar (US Regulatory)	Securities Registration Statement (simplified Form) (s-3/a)	NASDAQ:REPH	Recro Pharma Inc
14/01/2022	16:31	Edgar (US Regulatory)	Amended Current Report Filing (8-k/a)	NASDAQ:REPH	Recro Pharma Inc
06/01/2022	15:05	GlobeNewswire Inc.	Recro Reports Inducement Grants For New Staff	NASDAQ:REPH	Recro Pharma Inc
03/01/2022	06:00	GlobeNewswire Inc.	Recro to Present at H.C. Wainwright BioConnect 2022 Conference	NASDAQ:REPH	Recro Pharma Inc
02/12/2021	06:00	GlobeNewswire Inc.	Recro to Present at Stephens Annual Investment Conference	NASDAQ:REPH	Recro Pharma Inc